Back to Awarded Treatment Trials


Awarded Trial: 01T-420

Grant ID

01T-420

Illness

Schizophrenia

Primary Drug/Intervention

Celecoxib

Primary Dosage

400 mg

Secondary Drug Intervention

N/A

Secondary Dosage

N/A

Other Drug/Intervention

N/A

Other Dosage

N/A

Status

Completed

Investigator

Dolnak

Sample Size

35

Duration of Study Period for Each Subject

8 weeks

Outcome Measurements

PANSS, Calgary Depression, extra-pyramidal side effects and akathesia or quality of life scales

Results

Thirty-five subjects were randomized to receive celecoxib 400 mg given adjunctively to antipsychotics or placebo for eight weeks. No differences were found between groups on PANSS, Calgary Depression, extra-pyramidal side effect or quality of life scales. Soluble interleukin-2 receptor levels did not predict response to the drug.

Publication

Rapaport MH, Delrahim KK, Bresee CJ, Maddux RE, Ahmadpour O, Dolnak D. Celecoxib augmentation of continuously ill patients with schizophrenia. Biological Psychiatry 57:1594-1596, 2005.

Link

http://www.ncbi.nlm.nih.gov/pubmed/15953498

PI Name

Doug Dolnak

Degree

MD

Center

Department of Psychiatry

Institution

University of California

Address

8950 Villa la Jolla Drive, C207

City or Town

La Jolla

State or Province

CA

Zip or Postal Code

92037

Country

USA

Email Address

ddolnak@ucsd.edu